The Carmen and Severo Ochoa Foundation Award has been granted to the researcher Marisol Soengas, coordinator of the Melanoma Research Group at CNIO and member of our Scientific Advisory Board.
In this way, the XXVI edition of the award recognizes the scientific career of the researcher, dedicated to the basic and clinical study of melanoma. Her milestones include the identification of the “hallmarks of melanoma”, which differentiate it from other types of cancer, as well as the creation of a spin-off that already has a compound in clinical trials: BO-112, the first immunotherapy developed entirely in Spain.
She is the second person from our Scientific Advisory Board to receive this award. In 2003, Andrés Aguilera, researcher at CABIMER of the University of Seville, received this award.
The ceremony took place yesterday at the Royal National Academy of Medicine, where the attendees could also listen to the Commemorative Lecture “From biology to personalized treatment: the case of lung cancer” presented by Luis Paz Ares, president of ASEICA.
Related news on La Voz de Galicia, CNIO and Empresas con Salud
Image by CNIO